FAK activation drives non-genetic adaptive survival of ALK-rearranged lung cancer under tyrosine kinase inhibitor treatment

Xinru Chen; Jinhui Xue; Lin Zhang; Jie Huang; Songran Liu; Xinxin Zhang; Fan Wang; Yihua Huang; Jiani Zheng; Zhonghan Zhang; Yunpeng Yang; Hongyun Zhao; Jia-Xing Yue; Li Zhang; Jing Li

doi:10.1016/j.jgg.2026.04.023

Turn off MathJax

Article Contents

Article Navigation > Journal of Genetics and Genomics > 2026 > Accepted Manuscript

PDF( 0 KB)

FAK activation drives non-genetic adaptive survival of ALK-rearranged lung cancer under tyrosine kinase inhibitor treatment

doi: 10.1016/j.jgg.2026.04.023

a. Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong 510060, China;
b. Department of Medical Oncology, Shanghai East Hospital, Tongji University, Shanghai 200123, China;
c. Department of Clinical Research, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong 510060, China;
d. Department of Pathology, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong 510060, China;
e. State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong 510060, China;
f. The Affiliated Huaian No. 1 People’s Hospital of Nanjing Medical University, Northern Jiangsu Institute of Clinical Medicine, Nanjing Medical University, Huai’an, Jiangsu 223300, China;
g. Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, RNA Biomedical Institute, Phase I Clinical Trial Centre, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510120, China;
h. Department of Medical Oncology, Xiamen Key Laboratory of Antitumor Drug Transformation Research, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian 361003, China

Funds:

This work was supported by the Chinese National Natural Science Foundation Projects (82403727 to X.-R.C. and 82241232, 82272789 to L.Z.), Noncommunicable Chronic Diseases-National Science and Technology Major Project (2024ZD0519700 to L.Z.), Guangdong Pearl River Talents Program (2019QN01Y183 to J.-X.Y., 2021QN02Y168 to J.L.), Young Talents Program of Sun Yat-sen University Cancer Center (YTP-SYSUCC-0042 to J.-X.Y. and YTP-SYSUCC-0040 to J.L.), and Guangdong Basic and Applied Basic Research Foundation (2022A1515011873 to J.L.).

Received Date: 2025-10-26
Accepted Date: 2026-04-29
Rev Recd Date: 2026-04-27

Available Online: 2026-05-07

Abstract

FullText(HTML)

References(15)

References

Chen, T., Chen, X., Zhang, S., Zhu, J., Tang, B., Wang, A., Dong, L., Zhang, Z., Yu, C., Sun, Y., et al., 2021. The genome sequence archive family: toward explosive data growth and diverse data types. Genomics Proteomics Bioinformatics 19, 578-583.

Dawson, J.C., Serrels, A., Stupack, D.G., Schlaepfer, D.D., Frame, M.C., 2021. Targeting FAK in anticancer combination therapies. Nat. Rev. Cancer 21, 313-324.

Haderk, F., Chou, Y.T., Cech, L., Fernandez-Mendez, C., Yu, J., Olivas, V., Meraz, I.M., Barbosa Rabago, D., Kerr, D.L., Gomez, C., et al., 2024. Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer. Nat. Commun. 15, 3741.

Howlader, N., Forjaz, G., Mooradian, M.J., Meza, R., Kong, C.Y., Cronin, K.A., Mariotto, A.B., Lowy, D.R., Feuer, E.J., et al., 2020. The effect of advances in lung-cancer treatment on population mortality. N. Engl. J. Med. 383, 640-649.

Kwak, E.L., Bang, Y.J., Camidge, D.R., Shaw, A.T., Solomon, B., Maki, R.G., Ou, S.H., Dezube, B.J., Janne, P.A., Costa, D.B., et al., 2010. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363, 1693-1703.

Ma, Y., Song, Z., Chen, J., Zhao, Y., Fang, W., Guo, Y., Dong, Y., Yang, Y., Wu, G., Fang, J., et al., 2025. Safety, pharmacokinetic, pharmacodynamic, and efficacy properties of orally administered APG-2449 in patients with advanced ALK (+) and ROS1 (+) non-small-cell lung cancer: a multicentre, open-label, single-arm phase 1 trial. EClinicalMedicine 89, 103556.

Mok, T., Camidge, D.R., Gadgeel, S.M., Rosell, R., Dziadziuszko, R., Kim, D.W., Perol, M., Ou, S.I., Ahn, J.S., Shaw, A.T., et al., 2020. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann. Oncol. 31, 1056-1064.

Shaw, A.T., Yeap, B.Y., Mino-Kenudson, M., Digumarthy, S.R., Costa, D.B., Heist, R.S., Solomon, B., Stubbs, H., Admane, S., McDermott, U., et al., 2009. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J. Clin. Oncol. 27, 4247-4253.

Soda, M., Choi, Y.L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S., Watanabe, H., Kurashina, K., Hatanaka, H., et al., 2007. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448, 561-566.

Tanimura, K., Yamada, T., Horinaka, M., Katayama, Y., Fukui, S., Morimoto, K., Nakano, T., Tokuda, S., Morimoto, Y., Iwasaku, M., et al., 2021. Inhibition of c-Jun N-terminal kinase signaling increased apoptosis and prevented the emergence of ALK-TKI-tolerant cells in ALK-rearranged non-small cell lung cancer. Cancer Lett. 522, 119-128.

Tanimura, K., Yamada, T., Okada, K., Nakai, K., Horinaka, M., Katayama, Y., Morimoto, K., Ogura, Y., Takeda, T., Shiotsu, S., et al., 2022. HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal features. NPJ Precis. Oncol. 6, 5.

Tsuji, T., Ozasa, H., Aoki, W., Aburaya, S., Yamamoto Funazo, T., Furugaki, K., Yoshimura, Y., Yamazoe, M., Ajimizu, H., Yasuda, Y., et al., 2020. YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation. Nat. Commun. 11, 74.

Yanagimura, N., Takeuchi, S., Fukuda, K., Arai, S., Tanimoto, A., Nishiyama, A., Ogo, N., Takahashi, H., Asai, A., Watanabe, S., et al., 2022. STAT3 inhibition suppresses adaptive survival of ALK-rearranged lung cancer cells through transcriptional modulation of apoptosis. NPJ Precis. Oncol. 6, 11.

Yang, S.R., Schultheis, A.M., Yu, H., Mandelker, D., Ladanyi, M., Buttner, R., 2022. Precision medicine in non-small cell lung cancer: current applications and future directions. Semin. Cancer Biol. 84, 184-198.

You, D., Xin, J., Volk, A., Wei, W., Schmidt, R., Scurti, G., Nand, S., Breuer, E.K., Kuo, P.C., Breslin, P., et al., 2015. FAK mediates a compensatory survival signal parallel to PI3K-AKT in PTEN-null T-ALL cells. Cell Rep. 10, 2055-2068.

Relative Articles

Supplements(0)

Cited By

Proportional views